OKLAHOMA CITY, Nov. 30, 2020 (GLOBE NEWSWIRE) — Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO) of mammalian, microbial biologics and gene therapy plasmid DNA (pDNA), announces a new agreement with Nature Technology Corporation (NTC) for use of NTC’s proprietary HyperGRO manufacturing platform. This announcement is on the heels of Cytovance launching its Keystone Expression System® pDNA manufacturing licensing program.

“Our pDNA programs have greatly advanced due, in-part, to our use of NTC’s HyperGRO technology,” stated Bin Zhang, CEO of Cytovance Biologics. “We look forward to extending our collaborative work to benefit more clients with their gene therapy projects.”

Cytovance’s Keystone Expression System pDNA manufacturing platform is uniquely designed to process plasmids with low shear lysis and purification steps to produce high quality,…

Source link